T0	Participants 76 112	patients with chronic kidney disease
T1	Participants 194 229	patients with mild renal impairment
T2	Participants 386 450	patients who underwent percutaneous coronary intervention (PCI).
T3	Participants 494 613	patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial.
T4	Participants 614 672	Patients were randomly assigned to placebo or eptifibatide
T5	Participants 924 989	Patients with CrCl <60 ml/min were more likely to be older, women
T6	Participants 1645 1681	patients with mild renal impairment.